Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers

Substance-Related Disorders Clinical Trial

Official title: Modulation of Opiate Reward by NK1 Antagonism: A Laboratory-Based Proof of Concept Study

Status Active, not recruiting

Clinical Trial Summary

The objective of this study is to determine whether aprepitant blocks the opiate reward system in non-dependent opiate abusers, indicating its potential as a safe, non-addictive first line therapy for early heroin abuse.

Clinical Trial Description

This initial proof-of-concept study focuses on evaluating whether an NK1 antagonist, aprepitant, can block opiate reward in non-dependent opiate experienced volunteers in response to a standard opiate challenge. Sixty subjects will be included in a randomized controlled study. Following a training challenge session, they will receive 1 week treatment with aprepitant or matching placebo, followed by a challenge session during which subjective and physiological responses to the opiate partial agonist buprenorphine will be assessed. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Disease
• Heroin Dependence
• Opioid-Related Disorders
• Substance-Related Disorders

• NCT number: NCT00726960
• Study type: Interventional
• Source: Karolinska University Hospital
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: January 2008
• Completion date: June 2010